Ulcerative colitis (UC) is one of the two primary forms of inflammatory bowel disease. This condition is characterized by continuous mucosal inflammation that begins in the rectum and extends proximally throughout the colon. Common intestinal symptoms also include rectal bleeding, increased stool frequency, tenesmus, nocturnal bowel movements, and crampy abdominal pain. Acupuncture has been suggested as a potential intervention to alleviate clinical symptoms of UC. This single-center, parallel-group, two-arm, randomized, sham-controlled trial aims to evaluate the effects and safety of acupuncture for UC.

Start Date01 Nov 2024

Sponsor / Collaborator

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

ChiCTR2400090939 / SuspendedEarly Phase 1IIT

Application of transcutaneous acupoint electrical stimulation for postoperative gastrointestinal function recovery in patients undergoing laparoscopic colorectal tumor resection

Start Date17 Oct 2024

Sponsor / Collaborator

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

NCT06636422 / Not yet recruitingNot ApplicableIIT

Post-marketing Safety and Efficacy Surveillance of Motherwort Injection : a Registry Study

This study aims to provide evidence concerning the safety and efficacy of motherwort injection in real-world settings.

Start Date15 Oct 2024

Sponsor / Collaborator

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

100 Clinical Results associated with Guang'anmen Hospital, China Academy of Chinese Medical Sciences

0 Patents (Medical) associated with Guang'anmen Hospital, China Academy of Chinese Medical Sciences

199

Literatures (Medical) associated with Guang'anmen Hospital, China Academy of Chinese Medical Sciences

01 Sep 2024·Phytomedicine

Corrigendum to “The Efficacy and Safety of Bazi Bushen Capsule in Treating Premature Aging: A Randomized, Double Blind, Multicenter, Placebo-controlled Clinical Trial” [Phytomedicine. 2024 Jul 25; 130:155742]

Author: Xu, Fengqin ; Liu, Yanfei ; Zhang, Ping ; Yang, Qi ; Fang, Qingxia ; Zeng, Wenying ; Luo, Ran ; Huan, Luyao ; Huang, Yuxiao ; Wang, Biqing ; Zhang, Lirui ; Gao, Shanfeng ; Liu, Erjun ; Zhou, Shunlin ; Mei, Jun ; Liu, Yafeng ; Li, Jing ; Yang, Qiaoning ; Dong, Yan ; Gao, Rui ; Zhao, Junnan ; Zhang, Yanhong ; Wang, Xiaoyuan ; Zhao, Jiajun ; Zhang, Ying ; Qiu, Panbo ; Zhu, Fuli ; Meng, Hong ; Liu, Huiyan ; Yang, Limin ; Ju, Chunxiao ; Zhao, Ruihua ; Yin, Xueying ; Lu, YuHong

01 Aug 2024·International Immunopharmacology

Adipose-derived stem cell exosomes loaded with icariin attenuated M1 polarization of macrophages via inhibiting the TLR4/Myd88/NF-κB signaling pathway

Article

Author: Zhang, Zhiguo ; Song, Zhiqian ; Zhao, Yukun ; Chen, Yanjing ; Liu, Haixia ; Zhu, Ruyuan ; Li, Yubo ; Ma, Jiayi ; Yan, Qiqi ; Song, Changheng

Abnormal macrophage polarization is one of the common pathological bases of various inflammatory diseases. The current research focus involves targeting macrophages to remodel their phenotype as a treatment approach for inflammatory diseases. Notably, exosomes can be delivered to specific types of cells or tissues or inflammatory area to realize targeted drug delivery. Although icariin (ICA) exhibits regulatory potential in macrophage polarization, the practical application of ICA is impeded by its water insolubility, poor permeability, and low bioavailability. Exploiting the inherent advantages of exosomes as natural drug carriers, we introduce a novel drug delivery system-adipose-derived stem cells-exosomes (ADSCs-EXO)-ICA. High-performance liquid chromatography analysis confirmed a loading rate of 92.7 ± 0.01 % for ADSCs-EXO-ICA, indicating the successful incorporation of ICA. As demonstrated by cell counting kit-8 assays, ADSCs-EXO exerted a significantly higher promotion effect on macrophage proliferation. The subsequent experimental results revealed the superior anti-inflammatory effect of ADSCs-EXO-ICA compared to individual treatments with EXO or ICA in the lipopolysaccharide + interferon-gamma-induced M1 inflammation model. Additionally, results from enzyme-linked immunosorbent assay, quantitative polymerase chain reaction, and western blot analyses revealed that ADSCs-EXO-ICA effectively inhibited macrophage polarization toward the M1-type and concurrently promoted polarization toward the M2-type. The underlying mechanism involved the modulation of macrophage polarization through inhibition of the Toll-like receptor 4/myeloid differentiation factor 88/nuclear transcription factor-kappa B signaling pathway, thereby mitigating inflammation. These findings underscore the potential therapeutic value of ADSCs-EXO-ICA as a novel intervention for inflammatory diseases.

01 Jul 2024·JAMA Internal Medicine

Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities

Article

Author: Niu, Wenjuan ; Dai, Lina ; Li, Huan ; Wang, Lulu ; Hu, Li ; Zhao, Shuyu ; Zhao, Siyu ; Chen, Xi ; Wang, Jingwen ; Zhou, Tingting ; Zhang, Min ; Ma, Li ; Cai, Mengjie ; Wu, Qiong ; Wang, Huidan ; Li, Zhen ; Xu, Tianshu ; Juan, Yongjuan ; Tong, Xiaolin ; Zhang, Li ; Yan, Li ; Li, Jianxiu ; Huang, Nan ; Sun, Xueling ; Fan, Yuan ; Xu, Jing ; Zhang, Wendan ; Qiao, Gaohong ; Shi, Jing ; Lian, Fengmei ; Guo, Hui ; Zhang, Yuling ; Xu, Qinghua ; Zhao, Li ; Yang, Baijing ; Zhang, Congchao ; Yu, Acui ; Cheng, Hongwei ; Wang, Bingyan ; Sa, Ren ; Yang, Junyong ; Wei, Geng ; Song, Peizhen ; Gao, Wei ; Song, Aoran ; Xiao, Xinhua ; Fang, Qijun ; Li, Liyang ; Sun, Wenliang ; Huang, Li ; Lun, Liying ; Shi, Jilai ; Chen, Liming ; Liu, Yixuan ; Fang, Hui ; Han, Jialin ; Zheng, Jinxiang ; Zhang, Ruixia ; Cai, Xiaojun ; Zheng, Qingshan ; Wang, Huiling ; Kuang, Hongyu ; Ji, Hangyu ; Yin, Weiwei ; Wan, Jiale ; Pan, Xiaoxia ; Ye, Jianhua ; Li, Siyuan ; Zhang, Hong ; Pang, Ying ; Wang, Yanan ; Sun, Fengjun ; Lai, Yiwen ; Xu, Tong ; Liu, Haipeng ; Wang, Haiyan ; Yue, Lijun ; Liu, Xinhui ; Sheng, Yang ; Yao, Chen ; Wang, Li ; Liu, Hongli ; Zhang, Hewei ; Sang, Lili ; Chen, Xiufen ; Tian, Mengling ; Li, Minzhou ; Zhou, Rongrong ; Zhang, Xuanmin ; Cai, Guangyu ; Lu, Junhu ; Xie, Wenjiao ; Sun, Guanghui ; Jia, Zhenhua ; Dai, Yingran ; Hong, Wenhui ; Shi, Mengying ; Zhao, Xuefei ; Gan, Xia ; Cai, Xinlun ; Shang, Meixia ; Peng, Zedong ; Jing, Jingqing ; Li, Haoran ; Chen, Xinyan ; Huang, Ling ; Su, Yanjin ; Feng, Yurong ; You, Qin ; Gao, Huailin ; Li, Kaimin ; Hu, Xiaoyan ; Liu, Luyv ; Qin, Gangxin ; Han, Xu ; Piao, Chunli ; Hu, Sulin ; Chen, Ruyu ; Zhang, Liwei ; Zhang, Yaqin ; Zhao, Qiuju ; Tian, Wenhong ; Zang, Chunxue ; Li, Fan ; Zhou, Yun ; Song, Guangyao ; Wang, Xuling ; Luo, Junting

ImportancePrevious studies have shown that Jinlida (JLD) granules, an approved treatment for type 2 diabetes in China, can reduce blood glucose level, reduce glycated hemoglobin (HbA1c), and improve insulin resistance in people with type 2 diabetes.ObjectiveTo evaluate the effect of long-term administration of JLD vs placebo on the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities.Design, Setting, and ParticipantsThis multicenter, double-blind, placebo-controlled randomized clinical trial (FOCUS) was conducted across 35 centers in 21 cities in China from June 2019 to February 2023. Individuals aged 18 to 70 years with IGT and multiple metabolic abnormalities were enrolled.InterventionParticipants were randomly allocated 1:1 to receive JLD or placebo (9 g, 3 times per day, orally). They continued this regimen until they developed diabetes, withdrew from the study, were lost to follow-up, or died.Main Outcomes and MeasuresThe primary outcome was the occurrence of diabetes, which was determined by 2 consecutive oral glucose tolerance tests. Secondary outcomes included waist circumference; fasting and 2-hour postprandial plasma glucose levels; HbA1c; fasting insulin level; homeostatic model assessment for insulin resistance (HOMA-IR); total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels; ankle-brachial index; and carotid intima-media thickness.ResultsA total of 889 participants were randomized, of whom 885 were in the full analysis set (442 in the JLD group; 443 in the placebo group; mean [SD] age, 52.57 [10.33] years; 463 [52.32%] female). Following a median observation period of 2.20 years (IQR, 1.27-2.64 years), participants in the JLD group had a lower risk of developing diabetes compared with those in the placebo group (hazard ratio, 0.59; 95% CI, 0.46-0.74; P &lt; .001). During the follow-up period, the JLD group had a between-group difference of 0.95 cm (95% CI, 0.36-1.55 cm) in waist circumference, 9.2 mg/dL (95% CI, 5.4-13.0 mg/dL) in 2-hour postprandial blood glucose level, 3.8 mg/dL (95% CI, 2.2-5.6 mg/dL) in fasting blood glucose level, 0.20% (95% CI, 0.13%-0.27%) in HbA1c, 6.6 mg/dL (95% CI, 1.9-11.2 mg/dL) in total cholesterol level, 4.3 mg/dL (95% CI, 0.8-7.7 mg/dL) in low-density lipoprotein cholesterol level, 25.7 mg/dL (95% CI, 15.9-35.4 mg/dL) in triglyceride levels, and 0.47 (95% CI, 0.12-0.83) in HOMA-IR compared with the placebo group. After 24 months of follow-up, the JLD group had a significant improvement in ankle-brachial index and waist circumference compared with the placebo group.Conclusions and RelevanceThe findings suggest that JLD can reduce the risk of diabetes in participants with IGT and multiple metabolic abnormalities.Trial RegistrationChinese Clinical Trial Register: ChiCTR1900023241

100 Deals associated with Guang'anmen Hospital, China Academy of Chinese Medical Sciences

100 Translational Medicine associated with Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2 Clinical

Phase 3 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

The Yi-Qi-Qing-Jie herbal compound	Kidney Failure, Chronic More	Phase 3 Clinical
Yisuishengxue Granule	Transfusion-dependent Thalassemia More	Phase 2
YangWeiKangLiu Granules	Stomach Cancer More	Preclinical
BuShenZhuYun Decoction	Infertility More	Pending
Tang-min-ling pills	Diabetes Mellitus, Type 2 More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis